Matches in Wikidata for { <http://www.wikidata.org/entity/Q58082706> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q58082706 description "article scientifique publié en 2018" @default.
- Q58082706 description "artículu científicu espublizáu en payares de 2018" @default.
- Q58082706 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58082706 description "scientific article published on 01 November 2018" @default.
- Q58082706 description "wetenschappelijk artikel" @default.
- Q58082706 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q58082706 name "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 name "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 type Item @default.
- Q58082706 label "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 label "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 prefLabel "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 prefLabel "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 P1433 Q58082706-2C839D43-7923-4496-AF48-F4D39C08D9B2 @default.
- Q58082706 P1476 Q58082706-810348B2-A41E-4539-B01E-53F285520AA3 @default.
- Q58082706 P2093 Q58082706-76BE20FD-CF98-4E7F-837C-8A9F504F944B @default.
- Q58082706 P2093 Q58082706-B30A77AC-5416-40EF-97FB-B8A0144320A1 @default.
- Q58082706 P2093 Q58082706-B72727DF-3D5B-478A-907B-19E79B7605CB @default.
- Q58082706 P304 Q58082706-1AB40B37-71E2-45EE-85CC-2296A1D94E55 @default.
- Q58082706 P31 Q58082706-DE388BB7-22A9-4F5F-9B1C-247A33053D7B @default.
- Q58082706 P356 Q58082706-307F199F-AE3B-4611-A3A6-016D11B03CE4 @default.
- Q58082706 P407 Q58082706-87384EE2-9595-41EA-86AC-8B71F4909A88 @default.
- Q58082706 P433 Q58082706-942C0738-B2C5-433D-A1FD-262C6CCE2FD0 @default.
- Q58082706 P478 Q58082706-7752232B-4CBE-41DF-A44C-3A7CE3229B83 @default.
- Q58082706 P577 Q58082706-6A36710E-1134-4A47-B276-D9049A1A7882 @default.
- Q58082706 P698 Q58082706-7D10C25E-21B5-4FCF-8C6E-1E3D9178FCA8 @default.
- Q58082706 P921 Q58082706-1204B837-F57D-4274-9254-8CDD89602B62 @default.
- Q58082706 P921 Q58082706-4A33C58B-9AC8-406F-AA46-094A7B99718F @default.
- Q58082706 P356 J.JTHO.2018.07.012 @default.
- Q58082706 P698 30368417 @default.
- Q58082706 P1433 Q2448056 @default.
- Q58082706 P1476 "Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma" @default.
- Q58082706 P2093 "Coraline Dumenil" @default.
- Q58082706 P2093 "Etienne Giroux-Leprieur" @default.
- Q58082706 P2093 "Thierry Chinet" @default.
- Q58082706 P304 "e232-e234" @default.
- Q58082706 P31 Q13442814 @default.
- Q58082706 P356 "10.1016/J.JTHO.2018.07.012" @default.
- Q58082706 P407 Q1860 @default.
- Q58082706 P433 "11" @default.
- Q58082706 P478 "13" @default.
- Q58082706 P577 "2018-11-01T00:00:00Z" @default.
- Q58082706 P698 "30368417" @default.
- Q58082706 P921 Q356033 @default.
- Q58082706 P921 Q5186964 @default.